Evaluating Iron-Dependent Biomarkers of Malignant Glioma (WHO Grade IV) Progression
John M. Buatti
Summary
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
Description
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time. WHO grade IV gliomas are the most common primary brain tumors. Despite aggressive standard of care treatment, overall survival remains low. Early identification of whether the glioma comes back after a period of improvement (recurrence) remains an important part of treatment management. Early identification of recurrence can be complicated as treatment effects…
Eligibility
- Age range
- 21+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age \> 21 years * New pathologically confirmed diagnosis of WHO grade IV malignant glioma * KPS \> 60 * Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol Exclusion Criteria: * History of previous malignancy other than non-melanoma skin cancer in the previous 5 years * History of iron metabolic disorder such as hemochromatosis * Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices
Interventions
- ProcedureT2 (Observed)-Weighted Imaging
Undergo T2\* MRI
- ProcedureBiospecimen Collection
Undergo blood sample collection
- ProcedureMagnetic Resonance Imaging
Undergo standard MRI
Location
- University of Iowa Health CareIowa City, Iowa